NeoGenomics Inc. (NEO)
NEO trades on Nasdaq in Health Care, Precision Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1077183/000107718326000010/0001077183-26-000010-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NEO on Nasdaq |
| Sector | Health Care |
| Industry | Precision Instruments |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001077183 |
| SEC industry code | Services-Testing Laboratories |
| Incorporated in | NV |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $727.3M |
| Net income | -$108.0M |
| Operating income | Not in SEC XBRL data |
| Net margin | -14.9% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2021-09-01 |
| Latest annual report | 10-K | 2026-02-17 |
| Latest quarterly / interim | 10-Q | 2026-07-28 |
| Latest current report | 8-K | 2026-10-05 |
| Latest proxy | DEFA14A | 2026-04-06 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.7% |
| 1 month | -10.6% |
| 3 months | +13.7% |
| Year to date | +43.5% |
| 1 year | +80.7% |
| From 52-week high | -15.2% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Precision Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ULS | UL Solutions Inc. | $71.08 | -0.14% | $14.4B |
| AIDX | 20/20 Biolabs Inc. | $0.3513 | -4.02% | $4.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier